**Core Concept**
The question tests the student's knowledge of **nephrotoxicity** and **renal excretion** of anti-tuberculosis (TB) drugs. It requires understanding of how **renal impairment** affects the pharmacokinetics of these medications.

**Why the Correct Answer is Right**
Since the correct answer is not provided, let's discuss a commonly used anti-TB drug that can be safely given in patients with renal failure. **Ethambutol** is one such drug, but its dose needs adjustment in severe renal impairment. However, another drug, **Rifampicin**, is primarily hepatically metabolized and does not require dose adjustment in renal failure, making it a safer choice.

**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific drug, it's challenging to provide a detailed explanation. However, drugs like **Streptomycin** and **Capreomycin** are nephrotoxic and should be avoided in renal failure.
**Option B:** Similarly, without the specific drug, it's hard to comment. Yet, **Pyrazinamide** is primarily renally excreted and may require dose adjustment in renal impairment.
**Option C:** Again, lacking the specific drug, **Isoniazid** is another drug that requires caution and potential dose adjustment in renal failure due to its renal excretion.

**Why Each Wrong Option is Incorrect** (continued)
**Option D:** This option is also unspecified, but **Thiacetazone** is not commonly associated with renal toxicity concerns in the context of TB treatment adjustments for renal failure.

**Clinical Pearl / High-Yield Fact**
A crucial point to remember is that **Rifampicin** is a key drug in TB treatment regimens that is not significantly affected by renal impairment, making it a safer choice in patients with renal failure.

**Correct Answer:** Correct Answer: D. Rifampicin